1. P042 Decreased leukocyte trafficking may contribute to vedolizumab refractory disease after anti-TNF exposure in patients with ulcerative colitis. (16th January 2018) Authors: Verstockt, B; Verstockt, S; de Bruyn, M; Machiels, K; Blevi, H; Ballet, V; Van Assche, G; Vermeire, S; Ferrante, M Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P385 TREM1, the first anti-TNF specific biomarker guiding therapeutic decision. (25th January 2019) Authors: Verstockt, B; Verstockt, S; Dehairs, J; Ballet, V; Blevi, H; Wollants, W-J; Breynaert, C; Van Assche, G; Vermeire, S; Ferrante, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S300 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗